Drug intelligence / Profile preview

UI124

Development stage: Preclinical
Lead developer: Korea United Pharm
Modality: Small Molecules
Administration: Oral

Overview

UI124 is a small molecule drug candidate being developed by Korea United Pharm as an incrementally modified drug (IMD). It is a fixed-dose combination (FDC) therapy intended for use as a lipid-modifying agent to treat conditions such as dyslipidemia or hypercholesterolemia. As part of Korea United Pharm's pipeline of reformulations, UI124 is designed to improve patient compliance or therapeutic efficacy compared to existing monotherapies. It is currently in the formulation or early planning stages of development, with a projected launch in the early 2030s.

Beyond the preview

Go deeper on UI124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UI124.

Explore the full profile